The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository
暂无分享,去创建一个
A. Desautels | O. Monchi | A. Dagher | J. Poline | M. Lévesque | R. Postuma | M. Parent | M. Sharp | F. Cicchetti | G. Rouleau | M. Panisset | J. Gagnon | Samir Das | Z. Gan-Or | A. Lafontaine | S. Chouinard | C. Degroot | N. Dupré | J. Karamchandani | E. Fon | A. Genge | C. Melmed | E. Pourcher | J. Drouin-Ouellet | M. Langlois | T. Durcan | E. Leveille | Trisha Rao | Sonia Lai Wing Sun | Etienne Leveille
[1] A. Strafella,et al. Transcranial magnetic stimulation improves cognition over time in Parkinson's disease. , 2019, Parkinsonism & related disorders.
[2] D. Hernandez,et al. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset , 2019, npj Parkinson's Disease.
[3] Sonja W. Scholz,et al. Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.
[4] W. Chung,et al. SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[5] O. Monchi,et al. Common and rare GCH1 variants are associated with Parkinson's disease , 2019, Neurobiology of Aging.
[6] Sonja W. Scholz,et al. Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease , 2018, JAMA neurology.
[7] A. Singleton,et al. Finding useful biomarkers for Parkinson’s disease , 2018, Science Translational Medicine.
[8] R. Barker,et al. Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] W. Oertel,et al. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. , 2018, Parkinsonism & related disorders.
[10] R. Postuma,et al. The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies , 2018, Clinical genetics.
[11] E. Bézard,et al. Cardinal Motor Features of Parkinson’s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia , 2018, Journal of Parkinson's disease.
[12] A. Desautels,et al. Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder , 2018, Movement disorders : official journal of the Movement Disorder Society.
[13] J. Cedarbaum,et al. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] K. Marder,et al. Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.
[15] N. Dupré,et al. The influence of vascular risk factors on cognitive function in early Parkinson's disease , 2018, International journal of geriatric psychiatry.
[16] Réjean Plamondon,et al. Cranio-Caudal Kinematic Turn Signature Assessed with Inertial Systems As a Marker of Mobility Deficits in Parkinson’s Disease , 2018, Front. Neurol..
[17] Sonja W. Scholz,et al. Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease , 2017, Neurobiology of Aging.
[18] Patrick Boissy,et al. Using Inertial Sensors to Automatically Detect and Segment Activities of Daily Living in People With Parkinson’s Disease , 2018, IEEE Transactions on Neural Systems and Rehabilitation Engineering.
[19] G. Rouleau,et al. The Tanenbaum Open Science Institute: Leading a Paradigm Shift at the Montreal Neurological Institute , 2017, Neuron.
[20] Jean-François Gagnon,et al. REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson's Disease , 2017, Sleep.
[21] A. Dagher,et al. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.
[22] Y. Dauvilliers,et al. RIC3 variants are not associated with Parkinson's disease in French-Canadians and French , 2017, Neurobiology of Aging.
[23] Patrick Boissy,et al. Auto detection and segmentation of daily living activities during a Timed Up and Go task in people with Parkinson’s disease using multiple inertial sensors , 2017, Journal of NeuroEngineering and Rehabilitation.
[24] R. Alcalay,et al. Genetic Forms of Parkinson's Disease , 2017, Seminars in Neurology.
[25] N. Dupré,et al. Smoking history is associated to cognitive impairment in Parkinson's disease , 2017, Aging & mental health.
[26] O. Monchi,et al. Depressive symptoms in Parkinson’s disease correlate with cortical atrophy over time , 2017, Brain and Cognition.
[27] D. Louis Collins,et al. Cyberinfrastructure for Open Science at the Montreal Neurological Institute , 2017, Front. Neuroinform..
[28] D. Holtzman,et al. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. , 2017, The journal of prevention of Alzheimer's disease.
[29] R. Postuma,et al. Dementia Predictors in Parkinson Disease: A Validation Study. , 2017, Journal of Parkinson's disease.
[30] J. Volkmann,et al. Parkinson disease , 2017, Nature Reviews Disease Primers.
[31] C. Mariani,et al. Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.
[32] Tristan Glatard,et al. The MNI data-sharing and processing ecosystem , 2016, NeuroImage.
[33] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[34] Jean-François Gagnon,et al. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.
[35] B. Wang,et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.
[36] K. Marder,et al. Differential effects of severe vs mild GBA mutations on Parkinson disease , 2015, Neurology.
[37] O. Monchi,et al. Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease , 2014, Front. Neurol..
[38] T. Dall,et al. The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.
[39] Poul Jennum,et al. A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation study , 2012, Movement disorders : official journal of the Movement Disorder Society.
[40] Alan C. Evans,et al. LORIS: a web-based data management system for multi-center studies , 2012, Front. Neuroinform..
[41] D. Aarsland,et al. Nonlinear decline of mini‐mental state examination in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[42] M. Vidailhet,et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.
[43] A. Mirelman,et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease , 2010, neurogenetics.
[44] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[45] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[46] Enrico Marchioni,et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[47] Tore Wentzel-Larsen,et al. The rate of cognitive decline in Parkinson disease. , 2004, Archives of neurology.
[48] M. Onofrj,et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up , 2002, Neurological Sciences.